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This remains an important tenet, as up to 80% of persons with diabetes will suffer a cardiovascular event. This has led some to conclude that further risk stratification in persons with diabetes is neither warranted nor useful.
However, persons with diabetes are not all at equal risk. The data from PREDICT, 2 However, caution must be applied in the widespread application of such testing. Cost -effectiveness algorithms are just starting to be published, and the potential benefit of the increased knowledge provided by the test must be weighed against the radiation dose (albeit small for a calcium score only, unlike CT angiography, where doses can be 10-fold higher). Previous guidelines have suggested that these high-risk groups should not undergo calcium scoring; however, compelling data from these studies are likely to add to the impetus to update these recommendations.
If cost -effectiveness can be established, this would make it appealing to derive LDL targets based upon something more objective, such as a measure of the atherosclerosis burden. When clinical trial data are combined, including the Treating to
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New Targets (TNT) and Incremental Decrease in End Points
Through Aggressive Lipid Lowering (IDEAL) studies, maximal LDL lowering can be calculated to reduce cardiovascular events by 45-50%. Moreover, epidemiological studies imply that prolonged LDL lowering in primary prevention will reduce the risk even more. 11 Overall, the study by Elkeles et al. 2 adds important additional information to strengthen their conclusion that 'Measurement of CACS is a powerful predictor of cardiovascular events in asymptomatic patients with type 2 diabetes and can further enhance prediction provided by established risk models.' Thus, consideration for testing should be used in at least three diabetic subgroups that have been identified previously as targets for advanced risk stratification with cardiac CT. 12 These include patients with type I diabetes [up to 50% of whom will be identified as being at low risk based on a negative calcium scan (score ¼ 0)]; non-compliant patients (as several studies have demonstrated improved adherence with visualization of CAC) 13, 14 ; and younger diabetic patients (choosing a starting age for lipid-lowering and ACE inhibitor therapy is often arbitrary, and some younger patients may benefit from statin therapy). Identification of early plaque should allow better cardiovascular outcomes, as there are now robust therapies to treat patients identified as being at high risk. Furthermore, cost savings related to less pharmaceutical use for those found with no CAC (very low risk of cardiovascular shortterm events) should outweigh the cost of testing these populations.
Widespread use of CCS in persons at high risk (including those with diabetes) is not warranted, as widespread use of CCS will increase costs and may identify only a subset of patients who need increased therapies. A basic tenet that applies to all diagnostic testing must be applied to CCS as well: that a test should alter the treatment of the patient. If patients are already being treated aggressively, there is probably little or nothing to be gained by CCS testing. Alternatively, if the patient or physician is reluctant to treat a given diabetic patient maximally, then testing may help clarify the need (or lack thereof) of lipid-lowering therapy. Simply, this test will be useful for those for whom decisions concerning prevention strategies may be altered on the basis of the test results.
